Replies to post #3572 on Skye Bioscience Inc (SKYE)

[JohnCM]

Mono, thanks a bunch. Exactly what I was looking for.

[greenwillow]

Nice post.

NMUS in good hands.

Future looks great.

All have a great weekend.

GW

[cjarmstrong]

Fully diluted is actually ~110 million including warrants, could be less if some have expired.

[scottsmith]

This is the same Punit Dhillon behind oncs and inovio?

[TheMonolith]

NMUS DD

Fully Diluted O/S 88M shares!

“We welcome Nemus into Emerald’s family of life science companies,”

https://www.dailymarijuanaobserver.com/single-post/2018/01/19/NMUS-Nemus-Receives-400000-Under-Bridge-Loan-and-Closes-Private-Placement

Emerald holds a majority of Nemus’ common shares on a deemed fully converted basis. Nemus’ current directors have resigned, except for Dr. Brian Murphy, who has been joined by Punit Dhillon and Jim Heppell as directors of the company. Mr. Dhillon and Mr. Heppell are also directors of Emerald.

“We greatly value the intellectual capital and discovery capacity of the University of Mississippi, with which Nemus has an exclusive agreement for novel cannabinoid technologies. We will work to support the business and developmental vision of our CEO, Dr. Murphy, across a spectrum of medical indications of unmet need. The Emerald Board believes that Nemus presents a significant value proposition for investors and we look forward to advancing its pipeline into clinical development.”

http://beta.latimes.com/nation/la-na-pot-monopoly-20140529-story.html

"What makes the cannabis here on the campus of the University of Mississippi unique is that it is grown, processed and sold by the federal government. The stockpile represents the only source of pot allowed for researchers who want to conduct Food and Drug Administration-approved tests on using marijuana for medical purposes."

We intend to soon issue a pipeline development update reflecting the significant business opportunities available for our products and addressing molecule prioritization, associated goals, and timelines. We are looking forward to working with our new colleagues at Emerald and taking our first steps into human studies.”

Nemus Pipeline
http://www.nemusbioscience.com/research-and-cannabinoids/default.aspx

Nemus plans to utilize the capital raised to satisfy outstanding financial obligations and explore potential strategic opportunities which could possibly include a recapitalization plan and the potential uplisting of its shares onto a major stock exchange.

Emerald holds a majority of Nemus’ common shares on a deemed fully converted basis. Nemus’ current directors have resigned, except for Dr. Brian Murphy, who has been joined by Punit Dhillon and Jim Heppell as directors of the company. Mr. Dhillon and Mr. Heppell are also directors of Emerald.

http://emeraldhealth.ca/board-management/jim-heppell/#
http://emeraldhealth.ca/board-management/punit-dhillon/
http://emeraldhealth.ca/board-management/avtar-dhillon/

Lift Cannabis Expo | Interview with Chris Wagner

Chris Wagner, CEO of Emerland Health Therapeutics, explains Emerald's work with scientists and researchers around the world plus the importance of standardization, dosing and delivery - and more!

Great interview with Executive Chairman of Emerald Health Therapeutics, Dr. Avtar Dhillon.

https://www.directcannabisnetwork.com/meet-emerald-health-therapeutics/?utm_content=bufferc6a01&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer